Press Releases | PTC Therapeutics, Inc.

The press releases contained in this archive section are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. PTC Therapeutics disavows any obligation to update the information contained in such press releases after the date of their issuance.

Year

Aug 08, 2017

PTC Therapeutics Reports Second Quarter 2017 Financial Results and Provides Corporate Update

- Translarna™ second quarter sales of $45.8 M representing 197% growth over 2Q2016 -
- Over 1,200 patients on EMFLAZA™ 12 weeks into launch -
- ~400% dose-dependent increase in full length SMN2 mRNA shown in SUNFISH trial interim analysis -
- 2017 revenue guidance increased to $155-180 M -

Jul 25, 2017

PTC Therapeutics to Host Conference Call to Discuss Second Quarter Financial Results

SOUTH PLAINFIELD, N.J. , July 25, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its second quarter financial results and provide an update on the company's business and outlook on Tuesday, August 8, 2017 at

Jul 24, 2017

PTC Therapeutics Announces Promotion of Dr. Joseph McIntosh to Senior Vice President and Head of Clinical Development

SOUTH PLAINFIELD, N.J. , July 24, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the promotion of Joseph McIntosh , M.D. to Senior Vice President and Head of Clinical Development. Dr. McIntosh will be responsible for all aspects of Clinical Development across PTC's

Jul 18, 2017

PTC Therapeutics Announces Publication of Data from ACT DMD in The Lancet

SOUTH PLAINFIELD, N.J. , July 18, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the publication of the results of the ACT DMD trial study ataluren, the only treatment for the underlying cause of nonsense mutation Duchene muscular dystrophy (nmDMD), in the current issue

Jul 01, 2017

Preliminary Phase 2 Data from Spinal Muscular Atrophy Program Presented at CureSMA Conference

-- RG7916 demonstrated ~400% increase in SMN2 full length/Δ7 mRNA ratio --
-- RG7916 demonstrated a favorable preliminary safety profile and was generally well tolerated in Type 2/3 SMA patients --

Jun 30, 2017

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH PLAINFIELD, N.J. , June 30, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on June 27, 2017 it approved non-statutory stock options to purchase an aggregate of 74,750 shares of its common stock to seven new employees.

Jun 22, 2017

New Analyses of Translarna™ (ataluren) Data from ACT DMD Presented at the 12th Annual European Pediatric Neurology Society Congress

SOUTH PLAINFIELD, N.J. , June 22, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the presentation of new analyses utilizing alternative methods to understand the progression of Duchenne muscular dystrophy and the benefits of Translarna in nonsense mutation Duchenne

Jun 06, 2017

PTC Therapeutics Announces FDA Advisory Committee Meeting for Ataluren for the Treatment of Nonsense Mutation Dystrophinopathy

- September 28th is FDA's Tentative Date for Advisory Committee Meeting -

Jun 05, 2017

PTC Therapeutics Announces Executive Promotions

SOUTH PLAINFIELD, N.J. , June 5, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the appointments of Marcio Souza to Chief Operating Officer and Christine Utter to Principal Financial Officer and Treasurer. "I am extremely pleased to announce these promotions.

Jun 02, 2017

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH PLAINFIELD, N.J. , June 2, 2017 /PRNewswire/ -- PTC Therapeutics , Inc. (NASDAQ: PTCT) today announced that on May 30, 2017 it approved non-statutory stock options to purchase an aggregate of 46,000 shares of its common stock to seven new employees.

Pagination

First page
Previous page
…
Page 34
Page 35
Current page 36
Page 37
Page 38
…
Next page
Last page